Results 11 to 20 of about 432,821 (259)

Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review

Health and Quality of Life Outcomes, 2020
Background A Task Force from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) provides recommendations on how to systematically identify and appraise health state utility (HSU) weights for cost-effectiveness analyses.
Jacie T. Cooper, Andrew Lloyd, Juan Jose Garcia Sanchez, Elisabeth Sörstadius, Andrew Briggs, Phil McFarlane   +5 more
doaj   +1 more source

Overall survival of individuals with metastatic cancer in Sweden: a nationwide study

BMC Public Health, 2022
Aims Consistent improvements for overall survival (OS) have been reported for individuals with metastatic cancer. Swedish population-based registers allow national coverage and long follow-up time.
Greta Bütepage, Peter Carlqvist, Johanna Jacob, Asbjørn Toft Hornemann, Simona Vertuani   +4 more
doaj   +1 more source

Economic burden of cancer among patients with surgical resections of the lung, rectum, liver and uterus: results from a US hospital database claims analysis

Health Economics Review, 2017
Objectives To determine hospital resource utilization, associated costs and the risk of complications during hospitalization for four types of surgical resections and to estimate the incremental burden among patients with cancer compared to those without
Iftekhar Kalsekar, Chia-Wen Hsiao, Hang Cheng, Sashi Yadalam, Brian Po-Han Chen, Laura Goldstein, Andrew Yoo   +6 more
doaj   +1 more source

Understanding Diversity of Policies, Functionalities, and Operationalization of Immunization Information Systems and Their Impact: A Targeted Review of the Literature

Vaccines, 2023
The COVID-19 pandemic has focused attention on the use of immunization information systems (IIS) to record and consolidate immunization records from a variety of sources to generate comprehensive patient immunization histories.
Elizabeth A. Donckels, Luke Cunniff, Nina Regenold, Kaitlyn Esselman, Erik Muther, Alexandra Bhatti, Amanda L. Eiden   +6 more
doaj   +1 more source

A comparative study of orphan drug prices in Europe

Journal of Market Access & Health Policy, 2017
Background and Objective: This study assessed price differences by comparing annual treatment costs of similarly available orphan drugs in France, Germany, Italy, Norway, Spain, Sweden, and UK.
Katherine Eve Young, Imen Soussi, Michiel Hemels, Mondher Toumi   +3 more
doaj   +1 more source

Market Access and the Arrow of Time [PDF]

SSRN Electronic Journal, 2023
We revisit the natural experiments of division and unification of Germany now that more time has passed and more data have become available. We show that local market access shocks are not symmetric in time. The negative shock to local market access following the division of Germany lead to a fast and strong downward adjustment of the size of West ...
Klein, Marius, Rauch, Ferdinand
openaire   +3 more sources

Pediatric Market Access: A Qualitative Study. [PDF]

Ther Innov Regul Sci
Abstract Objectives This qualitative study aims to analyze current PM regulation and market access requirements and proposes potential solutions to mitigate current challenges. Methods Twenty-two semi-structured interviews were conducted with experts from pharmaceutical ...
Maas L, Joos A, Hiligsmann M.
europepmc   +3 more sources

Bioequivalence centres in Africa: current state and opportunities for growth

Journal of Pharmaceutical Policy and Practice
Bioequivalence studies are required for generic medicines to meet the same quality, safety, and efficacy standards as innovator products before receiving marketing authorisation. These studies compare the in vivo performance of a generic medicine to that
Bakani Mark Ncube, Sarah Muthuri, Olawale Ajose, Loice Kikwai   +3 more
doaj   +1 more source

The public health impact of recombinant herpes zoster vaccination in adults over 50 years in Spain

Human Vaccines & Immunotherapeutics
The recombinant zoster vaccine (RZV) is included in the Spanish National Immunisation Programme for adults 65 years of age (years), with a potential progressive catch-up program for adults 66–80 years, starting with 80 years.
Andrea García, Laura Amanda Vallejo-Aparicio, Rosario Cambronero Martinez   +2 more
doaj   +1 more source

Access to Credit in a Market Downturn

Journal of Financial Services Research, 2022
Abstract Using a unique proprietary dataset from a large European commercial bank containing granular loan-level information on credit lines to mid-corporate firms, we investigate the bank’s decisions to allow firms to retain existing credit at a time of acute financial instability. Our results highlight the importance of bank-firm relationships during
Barbara Casu, Laura Chiaramonte, Ettore Croci, Stefano Filomeni   +3 more
openaire   +4 more sources